The results demonstrated that Belzutifan was well‐tolerated and showed preliminary antitumor activity in heavily pretreated ccRCC patients and received U.S. Food and Drug Administration (FDA) approval in 2022 as the first HIF‐2α inhibitor for the treatment of VHL‐related diseases. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.